Integrative Molecular Medicine



Case Report ISSN: 2056-6360

The use of whole exome sequencing to identify carriers of Mosaic Variegated Aneuploidy (MVA): A case study

Munirah T Aljaser^{1*} and Shakir Bahzad²

¹Farwaniya Hospital - MOH, Kuwait

²Kuwait Medical Genetics Center, Kuwait

Abstract

Background: Whole-exome sequencing (WES) is a clinical diagnostic and research tool designed to identify and classify the arrangement of all protein-coding nuclear genes in the genome. Cases of infertility and recurrent miscarriages complicated by multiple-loop consanguinity may benefit from the implementation of whole-exome sequencing.

Case presentation: We report a case of a Kuwaiti consanguineous couple referred to the genetics department with a history of three live births followed by fourteen miscarriages, most of which occurred during the third and fourth months of gestation. The initial routine investigations including the blood tests, thyroid function, imaging, immunological and antibody profile, and chromosomal microarray of both parents were normal. The presence of multiple loops of consanguinity made making a correct diagnosis difficult. The option of whole-exome sequencing to examine the entire exome of both parents was proposed. After taking the patients' consent, the WES results of the couple revealed them both to be carriers of a previously unreported heterozygous variant of the CEP57 mutation resulting in multiple pregnancies with type 2 mosaic variegated aneuploidy that were incompatible with life.

Methods: Whole-exome sequencing was agreed by the treating clinical geneticists as a suitable option to identify the presence of a possible genetic mutation. The age, gender, ethnicity, medical history, family history, consanguinity, laboratory investigation results, clinical interpretation and implication of the results have been documented.

Conclusion: The reported case of infertility and recurrent miscarriages associated with multiple-loop consanguinity showed no abnormalities using conventional diagnostic methods. The application of whole-exome sequencing for the couple revealed them to be carriers for the type 2 mosaic variegated aneuploidy syndrome gene CEP57. In cases of multiple-loop consanguinity, whole-exome sequencing should be considered to aid in the diagnosis of the genetic mutations.

Introduction

Mosaic variegated aneuploidy (MVA), also known as Warburton-Ayane-Yeboa Syndrome, is classified by the Genetic and Rare Diseases (GARD) of the National Institute of Health (NIH) as a rare disease and has an autosomal recessive mode of inheritance [1]. MVA is classified into 2 types, MVA type 1 caused by BUB1B gene mutation and MVA type 2, which is less common and is caused by CEP57 gene mutation. Both types, however, result in defective chromosome separation during cell division [1].

The CEP57 gene plays a role in the stability and organization of cell spindle microtubules during cell division [2]. After the cell has duplicated the chromosomes, the spindle microtubules attach to the copies and pull them to opposite poles of the cell, ensuring that each new cell has one complete set of chromosomes; in MVA this organized separation does not occur resulting in mosaicism [2-4]. The CEP57 gene has also been linked to the transport of fibroblast growth factor 2 (FGF2), a signaling protein that regulates the development and growth of cells, along microtubules [2,5].

MVA is characterized by aneuploidy, most commonly presenting as monosomies or trisomies in cells. Due the random nature of the syndrome, the presentation varies from one case to the next. However, the most common features of MVA include intrauterine growth retardation (IUGR), microcephaly, brain abnormalities, and morphological anomalies such as low set ears and a broad nasal bridge

[2,3]. Additionally, MVA has been associated with certain malignancies such as rhabdomyosarcoma, leukemias, and Wilms tumor. 1

Case presentation

A married couple, a 38-year-old Kuwaiti woman and her husband, were referred to the genetics department by their treating gynecologist due a series of multiple and unexplained miscarriages. The couple have been in a consanguineous marriage (first degree paternal cousins) for the past 15 years. The husband was assessed to be healthy and had no significant past medical history. The wife was known to have hypothyroidism which was well-controlled and was being treated with eltroxin 100 mcg, she follows-up regularly with her endocrinologist.

Her obstetric history revealed the wife to be G17 P3 T2 A14 L2. The first two pregnancies were one year apart, both pregnancies were full-term, healthy girls with no complications. The third pregnancy produced a premature male diagnosed with Dandy-Walker syndrome. He died at 2 and a half years of age because of medical complications related to his condition. No DNA was obtained. The subsequent twelve pregnancies ended in miscarriage, all occurring in the third and fourth

*Correspondence to: Munirah T Aljaser, Farwaniya Hospital - MOH, Kuwait, Tel: 96551379990, E-mail: m.t.aljaser@gmail.com

Received: June 08, 2018; Accepted: June 20, 2018; Published: June 25, 2018

months of gestation. No tissue was karyotyped, and no DNA was banked from any of the fetuses. The sixteenth pregnancy was revealed by ultrasound to be a female fetus with severe cardiac and neurological anomalies. The patient miscarried in the fourth month of gestation and no DNA was obtained. The seventeenth pregnancy was also a female fetus with severe cardiac anomalies and was miscarried in the fourth month of gestation. No DNA was obtained.

The couple underwent full laboratory investigations. All of the investigations of the wife (Table 1) and husband (Table 2) came back

normal. Due to the couples' lineage being complicated by multiple loops of consanguinity, and their normal karyotype and chromosomal microarray results, it was decided that whole exome sequencing (WES) would be a suitable option for the couple to help reach a correct, and accurate diagnosis. The couple was counselled about the advantages and disadvantages of WES and they agreed to have proceed with the investigation.

The WES revealed that both the husband and the wife were carriers of mosaic variegated aneuploidy genes CEP57.

Table 1. Investigation results of the wife

Table 1. Investigation results of the wife Chromosome Analysis and peripheral blo Banding: G Chromosome number: 46 Autosomes: normal Sex Chromosomes: XX	od using G-banding techniqu	e:					
Mutation screening: Screening for G1619 à A mutation in fact The patient is not a carrier of any of the a	or V Leiden G20210 à A mut bove-mentioned mutations.	ation in prothrombin genes.					
Hematology:							
PT INR (ACT TOP 500)	1.08	0.88-1.13	INR				
*PT Patient	15.5	13-16	seconds				
*APTT Patient	32.6	26-34.4	seconds				
*APTT Ratio	1.09	0.87-1.13	(Ratio)				
PROTEIN S ACTIVITY	PROTEIN S ACTIVITY 93.8 63.5-149 %						
CBC:							
WBC	5.8	4.1-11.2	109/L				
RBC	4.12	3.83-5.08	1012/L				
HEMOGLOBIN	119	117-155	g/L				
HEMATOCRIT	0.361	0.345-0.463	L/L				
MCV	87.6	80.4-95.9	fL				
МСН	28.8	27.2-33.5	pg				
МСНС	329	325-352	g/L				
RDW	13.5	11.7-14.6	%				
PLATELET COUNT	279	150-410	109/L				
MPV	8.5	6.5-11.6	fL				
NEUTROPHILS %	44.4	39.9-73.9	%				
LYMPHOCYTES %	41.7	18.8-50.8	%				
MONOCYTES %	9	4.1-12.2	%				
EOSINOPHILS %	4.3	01-06	%				
BASOPHILS %	0.6	0.3-1.8	%				
NEUTROPHILS#	2.6	1.8-6.4	109/L				
LYMPHOCYTES#	2.4	1.2-3.6	109/L				
MONOCYTES #	0.5	0.3-0.9	109/L				
EOSINOPHILS#	0.2	0.1-0.5	109/L				
BASOPHILS#	0	0-0.02	109/L				
NUCLEATED RBC	0		WBC				
Antibody screening:							
Done by IF ENA profile (by IMMCO)							

(Transcript) (protein) Husband wife by	CEP57 (NM_014679.4)	c.56del	Het.	Het.	Not described	Frameshift	Not reported	Likely pathogenic (class 2)	Mosaic Variegated aneuploidy synddrome-2 (614114,AR)		
C-ANCA					_	In silico parameters	MAF	Variant classification	Disorder (OMIM#, inheritance)		
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti SSB (LA) NEGATIVE LEKM NEGATIVE Anti UI-an RNP-68 NEGATIVE ASMA NEGATIVE Anti UI-an RNP-C NEGATIVE Asti-MITO NEGATIVE Anti-UI-an RNP-C NEGATIVE Anti-Lodomystal NEGATIVE Anti-CI-70 Topolomeruse NEGATIVE Anti-Lodomystal Anti-CI-70 Topolomeruse NEGATIVE Anti-Lodomystal Anti-CI-70 Topolomeruse NEGATIVE <td< td=""><td>Gene</td><td>Nucleotide</td><td></td><td>Zvaosity</td><td></td><td>Whole Exome Sequ</td><td colspan="4">lencing:</td></td<>	Gene	Nucleotide		Zvaosity		Whole Exome Sequ	lencing:				
C-ANCA	FREE T3			4.88							
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE			2.25			0.27-4.2					
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE	PRL		228.9			72-511		mIU/L			
C-ANCA	FRT4		18.17			12-22		pmol/L			
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE			Result Value			Ref. Range		Unit			
C-ANCA					Thy	yroid function test:					
C-ANCA	Anti TG	Anti TG <100 IU/ml									
C-ANCA	Anti TPO		<	75 IU/ml							
C-ANCA	Anti CCP		<	<50 U/ml	Anti Insulin		<10 U/ml				
C-ANCA	RF IgM		<14 U/ml		Anti GAD		<5 U/ml				
C-ANCA	RF IgG		-	<20 U/ml		Anti IA2		<7.5 U/ml			
C-ANCA	RF IgA		<	<20 U/ml	An	ti Parietal cell Ab	<25 EU/ml				
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE	Anti B2GL-IgM 10		<	25 EU/ml	C	entromere Ab's			<25 EU/ml		
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE	Anti B2GL-Ig0	G 13	<	25 EU/ml	An	ti Intrinsic factor					
C-ANCA				<9 U/ml		Anti ss-DNA					
C-ANCA											
C-ANCA											
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE											
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-Fislet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti PM-SCL 100 NEGATIVE Anti CENP B NEGATIVE Anti HISTONE NEGATIVE Anti RIBO-P NEGATIVE Anti PCNA NEGATIVE NEGATIVE ntibody screening: Dine by ELISA technique Normal Range Normal Range Normal Range Anti ds-DNA <60 IU/ml					7111						
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti-HISTONE NEGATIVE Anti HISTONE NEGATIVE Anti HISTONE NEGATIVE Anti HISTONE NEGATIVE Anti PCNA NEGATIVE NORMAL NEGATI											
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE ANTI-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti U1-sn RNP C NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti-ISLET CENT NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITO NEGATIVE ANTI-MITONE				:60 IU/ml	O III/ml Anti CLIADINI CA						
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti-HISTONE NEGATIVE Anti HISTONE NEGATIVE Anti HISTONE NEGATIVE Anti RIBO-P NEGATIVE Anti PCNA NEGATIVE Anti PCNA NEGATIVE		Normal Re	inge		Diffe	by ELISA technique	Ne	ormal Range			
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti PM-SCL 100 NEGATIVE Anti PM-SCL 100 NEGATIVE Anti HISTONE NEGATIVE Anti HISTONE NEGATIVE Anti RIBO-P NEGATIVE Anti PCNA NEGATIVE	nuoody sercennig:				Dina	by FLISA technique					
C-ANCA NEGATIVE Anti-SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti-SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti PM-SCL 100 NEGATIVE Anti CENP B NEGATIVE Anti HISTONE NEGATIVE Anti RIBO-P NEGATIVE	antibody screenings					Anti PCNA	NEGATIVE				
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti PM-SCL 100 NEGATIVE Anti PM-SCL 100 NEGATIVE Anti CENP B NEGATIVE											
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE Anti-islet cell NEGATIVE Anti PM-SCL 75 NEGATIVE Anti-PM-SCL 100 NEGATIVE											
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Parietal cell NEGATIVE Anti JO-1 NEGATIVE Anti-Endomysial NEGATIVE Anti SCL-70 Topoiosmerase NEGATIVE											
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE Anti U1-sn RNP C NEGATIVE NEGATIVE	Anti-islet ce	11	NI	EGATIVE	Anti PM-SCL 75		NEGATIVE				
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE Anti-MITO NEGATIVE Anti U1-sn RNP C NEGATIVE	Anti-Endomys	sial	NI	EGATIVE	Anti SC	Anti SCL-70 Topoiosmerase		NEGATIVE			
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE ASMA NEGATIVE Anti U1-sn RNP A NEGATIVE	Parietal cel	1	NI	EGATIVE	Anti JO-1		NEGATIVE				
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE LKM NEGATIVE Anti U1-sn RNP 68 NEGATIVE	Anti-MITO)	NI	EGATIVE	Ar	nti U1-sn RNP C	NEGATIVE				
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE Anti-TG NEGATIVE Anti Smith (Sm) NEGATIVE	ASMA		NI	EGATIVE	Ar	nti U1-sn RNP A		NEGA	TIVE		
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE P-ANCA NEGATIVE Anti- SSB (LA) NEGATIVE	LKM		NEGATIVE		An	Anti U1-sn RNP 68		NEGATIVE			
C-ANCA NEGATIVE Anti- SSA (RO) 60 NEGATIVE	Anti-TG		NEGATIVE		Anti Smith (Sm)		NEGATIVE				
	P-ANCA	P-ANCA NEGATIVE		EGATIVE	Anti- SSB (LA)		NEGATIVE				
Anti-DNA NEGATIVE Anti-SS (RO) 52 NEGATIVE	C-ANCA		NI	EGATIVE	An	nti- SSA (RO) 60		NEGA	TIVE		
	Anti-DNA		NI	EGATIVE	A	anti-SS (RO) 52	NEGATIVE				

Table 2. Investigation results of the husband

Whole Exome Sequencing:									
Gene (Transcript)	Nucleotide (protein)	Zygosity		Described by	In silico parameters	MAF	Variant classification	Disorder (OMIM#,	
		Husband	wife	Described by	in sinco parameters	WIAF	variant classification	inheritance)	
CEP57 (NM_014679.4)	c.56del	Het.	Het.	Not described	Frameshift	Not reported	Likely pathogenic (class 2)	Mosaic Variegated aneuploidy synddrome-2 (614114,AR)	

Chromosome Analysis and peripheral blood using G-banding technique:

Banding: G

Chromosome number: 46 Autosomes: normal Sex Chromosomes: XY

Management and outcome

Taking into consideration the fact that both patients are confirmed carriers of MVA CEP57 gene, the previous fourteen consecutive miscarriages, the mothers age, and the social and cultural background of the couple. It was decided that Invitro Fertilization (IVF) and preimplantation genetic diagnosis (PGD) would be the most appropriate solution if they intended to continue growing their family. Ultimately, the couple decided that they wanted to initiate the IVF-PGD process.

Discussion

The presentation and the pedigree of the case was unique. While the couple presented to the clinic to address recurrent miscarriages, the lack of fetal tissue, the lack of clinically significant lab results, in addition to the multiple consanguineous loops (Figure 1) made reaching a diagnosis difficult.

It was approached as a case of infertility. The patients underwent assessment for structural anomalies which returned normal. The hormonal profiles of the couple were normal. The Immunology panel including anti-dsDNA, anti-TPO, anti-TG, anti-cardiolipin, anti-phospholipid, and anti-ssDNA, as well as the hematological results, were normal.

The treating team decided to proceed to genetic testing of both patients. The karyotype of the wife and husband was normal. Chromosomal microarray identified homozygosity compromising about 2.26% of the genome, which does not match the percentage of homozygosity expected of a first-degree cousin marriage who have multiple loops of consanguinity in their family history [5].

The couple agreed to WES and the results showed that both the husband and wife were carriers for the pathogenic CEP57 gene mutation, making them both carriers of type 2 mosaic variegated aneuploidy syndrome. Coincidentally, they were carriers of a previously unreported heterozygous variant in the CEP57 gene. The Exome aggregation consortium had no previous record of this variant and at the time of detection, this variant had not been listed in CentoMD*.

This CEP57 mutation creates a frameshift at the Ala19 and a stop codon 18 positions downstream that likely leads to truncation of the translated protein. MVA type 2 is known to be an autosomal recessive syndrome which results in defective cell division. The resultant chromosomal disjunction during mitosis leads to a variety of phenotypic abnormalities [6]. Unlike MVA type 1, MVA type 2 patients usually have normal head circumferences and slow growth rates. Additionally, MVA type 2 has been associated with shorter upper limbs [2].

This is the first time reporting a couple who are both carriers of the same new variant of the CEP57 mutation and is also the first time reporting multiple successive miscarriages caused by MVA type 2.




Figure 1. The genetic pedigree of the patients

The occurrence of this case may be attributed to the high rates of consanguineous marriages in the Middle East, which was estimated to be between 30 to 50% or more of the population [7]. These rates are greatly influenced by the cultural traditions and social customs of the area [7]. It is customary among the Bedouin and tribal families of the region to marry first cousin to first cousin. As a consequence of these marriages, there are higher rates of genetic diseases in these areas [7]. The only way to impact the high rates of inherited genetic syndromes in these groups would be to focus on educating the population on the risks and potential outcomes of these marriages, focusing on counselling families that are known to be carriers of genetic syndromes about the risks involved in consanguineous marriages, and by establishing governmental programs that screen for the most common genetic diseases.

References

- Hanks S, Snape K, Rahman N (2012) Mosaic variegated aneuploidy syndrome. Atlas Genet Cytogenet Oncol Haematol 16: 376-380.
- García-Castillo H, Vásquez-Velásquez AI, Rivera H, Barros-Núñez P (2008) Clinical and genetic heterogeneity in patients with mosaic variegated aneuploidy: delineation of clinical subtypes. Am J Med Genet A 146A: 1687-1695. [Crossref]
- 3. Mosaic variegated aneuploidy syndrome (2012) Online Mendelian Inheritance in Man.
- Meunier S, Navarro MG, Bossard C, Laurell H, Touriol C, et al. (2009) Pivotal role
 of translokin/CEP57 in the unconventional secretion versus nuclear translocation of
 FGF2. Traffic 10: 1765-1772. [Crossref]
- Woods C, Cox J, Springell K, Hampshire D, Mohamed M, et al. (2006) Quantification of homozygosity in consanguineous individuals with autosomal recessive disease. Am J Hum Genet 78: 889-896.

Aljaser MT (2018) The use of whole exome sequencing to identify carriers of Mosaic Variegated Aneuploidy (MVA): A case study

Copyright: ©2018 Aljaser MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Integr Mol Med, 2018 doi: 10.15761/IMM.1000332 Volume 5(3): 5-5